What is the prognosis of Hürthle cell carcinoma?

1. [Guideline] Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016 Jan. 26 (1):1-133. [Medline]. [Full Text].

2. Yeh MW, Bauer AJ, Bernet VA, et al. American thyroid association statement on preoperative imaging for thyroid cancer surgery. Thyroid. 2015 Jan. 25(1):3-14. [Medline].

3. Tufano RP, Clayman G, Heller KS, et al. Management of recurrent/persistent nodal disease in patients with differentiated thyroid cancer: a critical review of the risks and benefits of surgical intervention versus active surveillance. Thyroid. 2015 Jan. 25(1):15-27. [Medline].

4. Dal Maso L, Tavilla A, Pacini F, et al. Survival of 86,690 patients with thyroid cancer: A population-based study in 29 European countries from EUROCARE-5. Eur J Cancer. 2017 Apr 11. 77:140-52. [Medline].

5. Weir HK, Thompson TD, Soman A, et al. The past, present, and future of cancer incidence in the United States: 1975 through 2020. Cancer. 2015 Feb 3. [Medline].

6. Davies L, Welch HG. Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg. 2014 Apr. 140 (4):317-22. [Medline].

7. Morris LG, Sikora AG, Tosteson TD, Davies L. The increasing incidence of thyroid cancer: the influence of access to care. Thyroid. 2013 Jul. 23(7):885-91. [Medline]. [Full Text].

8. Melville N. Papillary Thyroid Cancer Overdiagnosed; Therapy Unnecessary. Medscape [serial online]. Available at http://www.medscape.com/viewarticle/808401. Accessed: August 4, 2013.

9. Le KT, Sawicki MP, Wang MB, Hershman JM, Leung AM. HIGH PREVALENCE OF AGENT ORANGE EXPOSURE AMONG THYROID CANCER PATIENTS IN THE NATIONAL VA HEALTHCARE SYSTEM. Endocr Pract. 2016 Jan 27. [Medline].

10. Gharib H, Goellner JR. Fine-needle aspiration biopsy of the thyroid: an appraisal. Ann Intern Med. 1993 Feb 15. 118(4):282-9. [Medline].

11. Brooks M. Low-risk thyroid cancer overdiagnosed, overtreated. Medscape Medical News. August 28, 2013. [Full Text].

12. Brito JP, Morris JC, Montori VM. Thyroid cancer: zealous imaging has increased detection and treatment of low risk tumours. BMJ. 2013 Aug 27. 347:f4706. [Medline].

13. Belfiore A, La Rosa GL, La Porta GA, et al. Cancer risk in patients with cold thyroid nodules: relevance of iodine intake, sex, age, and multinodularity. Am J Med. 1992 Oct. 93(4):363-9. [Medline].

14. Kim SH, Kim KH, Park HS, et al. Factors related with metastasis of right retroesophageal lymph nodes in papillary thyroid cancer. Minerva Chir. 2015 Feb. 70(1):1-5. [Medline].

15. Barney BM, Hitchcock YJ, Sharma P, Shrieve DC, Tward JD. Overall and cause-specific survival for patients undergoing lobectomy, near-total, or total thyroidectomy for differentiated thyroid cancer. Head Neck. 2011 May. 33(5):645-9. [Medline].

16. Asari R, Koperek O, Scheuba C, Riss P, Kaserer K, Hoffmann M. Follicular thyroid carcinoma in an iodine-replete endemic goiter region: a prospectively collected, retrospectively analyzed clinical trial. Ann Surg. 2009 Jun. 249(6):1023-31. [Medline].

17. Busko M. Study supports selective RAI use in papillary thyroid cancer. Medscape Medical News. June 28, 2013. [Full Text].

18. Nixon IJ, Ganly I, Patel SG, Palmer FL, Di Lorenzo MM, Grewal RK, et al. The results of selective use of radioactive iodine on survival and on recurrence in the management of papillary thyroid cancer, based on memorial sloan-kettering cancer center risk group stratification. Thyroid. 2013 Jun. 23(6):683-94. [Medline].

19. Ruel E, Thomas S, Dinan M, et al. Adjuvant radioactive iodine therapy is associated with improved survival for patients with intermediate risk papillary thyroid cancer. J Clin Endocrinol Metab. 2015 Feb 2. jc20144332. [Medline].

20. Nelson R. Sorafenib potent new tx for advanced thyroid cancer. Medscape Medical News. June 2, 2013. Available at http://www.medscape.com/viewarticle/805175. Accessed: June 17, 2013.

21. Brose MS, Nutting C, Jarzab B, et al. Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: the Phase 3 DECISION trial. Presented at the 49th Annual Meeting of the American Society of Clinical Oncology; June 2, 2013; Chicago, IL. Abstract 4.

22. Berdelou A, Lamartina L, Klain M, Leboulleux S, Schlumberger M, TUTHTYREF Network. Treatment of refractory thyroid cancer. Endocr Relat Cancer. 2018 Apr. 25 (4):R209-23. [Medline]. [Full Text].

23. Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015 Feb 12. 372(7):621-30. [Medline].

24. FDA. FDA approves Lenvima for a type of thyroid cancer. US Food and Drug Administration. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm434288.htm. Accessed: Feb 18 2015.

25. Nguyen XV, Roy Choudhury K, Tessler FN, Hoang JK. Effect of Tumor Size on Risk of Metastatic Disease and Survival for Thyroid Cancer: Implications for Biopsy Guidelines. Thyroid. 2018 Feb 22. [Medline].

26. Swegal WC, Singer M, Peterson E, et al. Socioeconomic Factors Affect Outcomes in Well-Differentiated Thyroid Cancer. Otolaryngol Head Neck Surg. 2016 Mar. 154 (3):440-5. [Medline].

27. Ain KB. Anaplastic thyroid carcinoma: behavior, biology, and therapeutic approaches. Thyroid. 1998 Aug. 8(8):715-26. [Medline].

28. Tafinlar (dabrafenib) [package insert]. East Hanover, New Jersey 07936: Novartis Pharmaceuticals Corporation. May 2018. Available at [Full Text].

29. Mulcahy N. FDA OKs Targeted Therapy Combo for Anaplastic Thyroid Cancer. Medscape Medical News. 2018 May 4. [Full Text].

30. Salari B, Hammon RJ, Kamani D, Randolph GW. Staged Surgery for Advanced Thyroid Cancers: Safety and Oncologic Outcomes of Neural Monitored Surgery. Otolaryngol Head Neck Surg. 2017 Apr 1. 194599817697189. [Medline].

31. [Guideline] Wells SA Jr, Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015 Jun. 25 (6):567-610. [Medline]. [Full Text].

32. [Guideline] Smallridge RC, Ain KB, Asa SL, et al. American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid. 2012 Nov. 22 (11):1104-39. [Medline]. [Full Text].

33. [Guideline] NCCN Clinical Practice Guidelines in Oncology: Thyroid Carcinoma. Version l.2016. National Comprehensive Cancer Network. Available at https://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf. July 8, 2016; Accessed: September 18, 2016.

34. [Guideline] Gharib H, Papini E, Garber JR, et al. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ASSOCIAZIONE MEDICI ENDOCRINOLOGI MEDICAL GUIDELINES FOR CLINICAL PRACTICE FOR THE DIAGNOSIS AND MANAGEMENT OF THYROID NODULES--2016 UPDATE. Endocr Pract. 2016 May. 22 (5):622-39. [Medline]. [Full Text].

35. Ha EJ, Na DG, Baek JH, Sung JY, Kim JH, Kang SY. US Fine-Needle Aspiration Biopsy for Thyroid Malignancy: Diagnostic Performance of Seven Society Guidelines Applied to 2000 Thyroid Nodules. Radiology. 2018 Feb 21. 171074. [Medline].

36. Cibas ES, Ali SZ. The Bethesda System for Reporting Thyroid Cytopathology. Thyroid. 2009 Nov. 19 (11):1159-65. [Medline].

37. Cibas ES, Ali SZ. The 2017 Bethesda System for Reporting Thyroid Cytopathology. Thyroid. 2017 Nov. 27 (11):1341-6. [Medline]. [Full Text].

38. Nelson R. Thyroid Nodules: Bethesda System Update Changes Clinical Practice. Medscape. 2018 Jan 9. [Full Text].

39. [Guideline] American Thyroid Association Guidelines Task Force, Kloos RT, Eng C, et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid. 2009 Jun. 19 (6):565-612. [Medline]. [Full Text].

40. FDA. FDA approves Nexavar to treat type of thyroid cancer. US Food and Drug Administration. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm376443.htm. Accessed: December 2, 2013.

41. Goldfarb M, Freyer DR. Comparison of secondary and primary thyroid cancer in adolescents and young adults. Cancer. 2014 Feb 24. [Medline].

42. Melanoma Risk Increased in Patients With Papillary Thyroid Carcinoma. Medscape. Mar 24 2014. [Full Text].

43. Mulcahy N. When Secondary, Thyroid Cancer May Be More Dangerous in Youth. Medscape Medical News. Feb 25 2014. [Full Text].

44. Oakley GM, Curtin K, Layfield L, et al. Increased melanoma risk in individuals with papillary thyroid carcinoma. JAMA Otolaryngol Head Neck Surg. 2014 Mar 13. [Medline].

Pramod K Sharma, MD Consulting Staff, Ear, Nose and Throat Center

Pramod K Sharma, MD is a member of the following medical societies: American Academy of Otolaryngology-Head and Neck Surgery, American College of Surgeons, American Head and Neck Society, The Triological Society, American Medical Association, American Rhinologic Society, Society of University Otolaryngologists-Head and Neck Surgeons, Utah Medical Association

Disclosure: Nothing to disclose.

Michael M Johns, MD Director of USC Voice Center, Division Director of Laryngology, Professor, USC Tina and Rick Caruso Department of Otolaryngology-Head and Neck Surgery, Keck School of Medicine of the University of Southern California

Michael M Johns, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Otolaryngology-Head and Neck Surgery, American Bronchoesophagological Association, Phi Beta Kappa, Voice Foundation

Disclosure: Nothing to disclose.

Kemp M Anderson Medical University of South Carolina College of Medicine

Kemp M Anderson is a member of the following medical societies: Association of American Medical Colleges, American Medical Association

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Nader Sadeghi, MD, FRCSC Professor and Chairman, Department of Otolaryngology-Head and Neck Surgery, McGill University Faculty of Medicine; Chief Otolaryngologist, MUHC; Director, McGill Head and Neck Cancer Program, Royal Victoria Hospital, Canada

Nader Sadeghi, MD, FRCSC is a member of the following medical societies: American Academy of Otolaryngology-Head and Neck Surgery, American Head and Neck Society, American Thyroid Association, Royal College of Physicians and Surgeons of Canada

Disclosure: Nothing to disclose.

Arlen D Meyers, MD, MBA Professor of Otolaryngology, Dentistry, and Engineering, University of Colorado School of Medicine

Arlen D Meyers, MD, MBA is a member of the following medical societies: American Academy of Facial Plastic and Reconstructive Surgery, American Academy of Otolaryngology-Head and Neck Surgery, American Head and Neck Society

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: Cerescan;RxRevu;Cliexa;The Physicians Edge;Sync-n-Scale;mCharts<br/>Received income in an amount equal to or greater than $250 from: The Physicians Edge, Cliexa<br/> Received stock from RxRevu; Received ownership interest from Cerescan for consulting; .

Samia Nawaz, MBBS, MD Associate Professor, Department of Pathology, University of Colorado Health Science Center

Samia Nawaz, MBBS, MD is a member of the following medical societies: American Society for Clinical Pathology, American Society of Cytopathology, International Academy of Pathology

Disclosure: Nothing to disclose.